Curenetics
UK biotech-quantum startup applying quantum algorithms and AI to cancer vaccine target identification.
Last refreshed: 22 April 2026 · Appears in 1 active topic
Can quantum neoantigen discovery give Curenetics a licensing deal before clinical trials are even necessary?
Timeline for Curenetics
Received DTC Quantum grant for quantum-AI cancer vaccine target research
UK Startups and Innovation: DTC Quantum names four Harwell cohort firms- What is Curenetics and what does it do?
- Curenetics is a UK biotech-quantum startup applying quantum-adjacent algorithms and AI to identify cancer vaccine targets (neoantigen discovery). It was named in the April 2026 DTC Quantum cohort at Harwell.Source: Lowdown / UKRI STFC
- How does quantum computing help with cancer vaccine research?
- Identifying neoantigens — mutant protein fragments that can be targeted by personalised cancer vaccines — is a combinatorially hard optimisation problem that quantum algorithms can tackle more efficiently than classical computing at scale.
- What funding did Curenetics receive from the DTC Quantum programme?
- Curenetics received £50,000 to £100,000 in R&D funding, 50 hours of business support, and investor introductions as part of the April 2026 DTC Quantum cohort at Harwell.Source: UKRI STFC / NQCC
- What is neoantigen discovery in personalised cancer treatment?
- Neoantigen discovery identifies tumour-specific mutant protein fragments that distinguish cancer cells from healthy ones. These neoantigens are used to design personalised cancer vaccines that train the immune system to attack the tumour.
Background
Curenetics was named on 16 April 2026 in the inaugural DeepTech Catalyst Quantum (DTC Quantum) cohort at Harwell, delivered by UKRI STFC and the National Quantum Computing Centre (NQCC). Each cohort member receives £50,000 to £100,000 in R&D funding, 50 hours of business support, and investor introductions under the UK's £2bn ProQure quantum programme.
Curenetics is a UK biotech-quantum crossover startup that applies quantum-adjacent algorithms and classical AI to the identification of cancer vaccine targets — specifically to neoantigen discovery, the process of identifying the mutant protein fragments on a tumour cell that the immune system can be trained to attack. Neoantigen selection is a combinatorially hard problem well suited to quantum-inspired optimisation; Curenetics' approach positions it alongside established mRNA cancer-vaccine pipelines developed by BioNTech and Moderna, both of which are advancing personalised cancer vaccines through Phase II and Phase III trials.
Curenetics represents the healthcare vertical within DTC Quantum and is the cohort's highest-stakes commercial proposition: cancer vaccine development operates on long regulatory timelines, but a validated neoantigen-selection platform could be licensed to major biopharmaceutical firms independent of a full drug programme. Whether the DTC Quantum grant accelerates a licensing deal or private investment within 18 months is the benchmark the programme has set for itself.